Teva Pharma (TEVA) Tops Q3 EPS by 11c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Teva Reports Third Quarter 2018 Financial Results
November 1, 2018 7:00 AM EDTRevenues of $4.5 billion Free cash flow of $704 million GAAP diluted loss per share of $0.27 Non-GAAP diluted EPS of $0.68 Spend base reduction of $1.8 billion in the first nine months of 2018; on-track to achieve $3.0 billion by the end of 2019 AJOVY (fremanezumab) was approved by the FDA in September 2018 and immediately launched Raising 2018 full year guidance: Non-GAAP EPS guidance raised to $2.80-2.95 from $2.55-2.80 Free cash flow guidance raised to $3.6-3.8 billion from... More
